PROTHENA CORP PUBLIC LTD CO
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Accelerated filer
State of Incorporation
Ireland
Business Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2, L2, D02 VK60
Mailing Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2, L2, D02 VK60
Phone
011-353-1-236-2500
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$547.11M
Total Assets
$618.83M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| DEF 14A Definitive proxy statement | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 8-K Current report of material events | February 27, 2026 | View on SEC |
| 10-K Annual financial report | February 27, 2026 | View on SEC |
Annual Reports
10-K
February 27, 2026
- Advancing a pipeline of novel therapies for severe neurodegenerative and rare peripheral amyloid diseases.
- Maintains strong strategic collaborations with major pharmaceutical companies like Roche, Bristol Myers Squibb, and Novo Nordisk.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.